This #RareDiseaseDay, we highlight #frontotemporaldementia and the need for new treatments. We are working on innovative therapies to elevate progranulin levels for the genetic form of #FTD. Learn more: loom.ly/WkGeVEQ

#News: Today we announced our fourth quarter and full-year 2024 #financialresults. Read the full press release for more information on our company and our lead #genetherapy program in patients with #frontotemporaldementia: loom.ly/vdCrFGE

This #InternationalWomensDay, we celebrate the women at Passage Bio who are driving innovation in genetic medicine. Their dedication is shaping the future for patients with neurodegenerative diseases like FTD. #IWD2025 #WomenInSTEM

#ICYMI: Our CEO, Will Chou, shared insights on our mission to redefine the future of genetic medicines for neurodegenerative diseases at the Leerink Global Biopharma Conference. Catch the full webcast here: loom.ly/WfjhkuQ #Biopharma #GeneticMedicines

Our Chief Scientific Officer, Susan Browne, is presenting at the AD/PD 2025 Conference in Vienna. Join us to learn more about our latest research in #frontotemporaldementia and GRN mutations. Learn more about the conference here: loom.ly/YoOf7E4 #ADPD2025 #meded

We presented encouraging data from our ongoing upliFT-D clinical trial in #frontotemporaldementia at #ADPD2025. Exciting progress is being made, and we’re committed to driving #innovation in #geneticmedicine. To view our presentation, visit: loom.ly/NQfz__U #meded

Proud to support the The AFTD Hope Rising Benefit alongside dedicated advocates working to make a difference for those affected by #FTD. These efforts help drive #research forward and bring us closer to a cure. #FTDAwareness

The Passage Bio team was honored to sponsor and attend the The AFTD Education Conference in support of the #FTD community. We are grateful to be part of a movement driving progress in research, care and resources. #GeneticMedicine

This #HDAwarenessMonth, we remain driven by a bold mission: to change the trajectory of #Huntingtonsdisease and other neurodegenerative conditions with the power of genetic medicine. #GeneticMedicine #HD

This morning, we announced our first quarter 2025 #financialresults and recent #business highlights. Learn more about our achievements and upcoming milestones here: loom.ly/uLTeANE $PASG

On #MemorialDay, we pause to remember the heroes who gave their lives in service to our nation.

We were proud to share new process development data for our gene therapy candidate at the ASGCT Annual Meeting. Our internally developed, suspension-based manufacturing process showed substantial gains in productivity, purity, and full capsids: loom.ly/BgLRvDI

Our Patient Advocacy team hosted a reTHINK with Dementia workshop in partnership with Fortheirthoughts. The session gave participants a deeper, more personal understanding of what it’s like to live with #dementia, helping to build empathy, connection, and better care.

We observe #Juneteenth as a company holiday giving our team time to reflect, learn, and support their communities. At Passage Bio, inclusion, equity, and respect are core to who we are. Today and every day, we stand for justice.

#NEWS: Today we reported updated interim data from the ongoing Phase 1/2 upliFT-D #clinicaltrial evaluating our potential treatment for frontotemporal #dementia (#FTD) with granulin (GRN) mutations. Read about the data and program updates here: bit.ly/4k0e6xm #meded

We’re deeply saddened by the passing of our colleague and friend, Chip Cale, Passage Bio’s General Counsel. Chip’s authenticity, spirit, and dedication left a lasting impact on all who knew him. Our thoughts are with his family and loved ones. loom.ly/MHsVGDk

From all of us at Passage Bio, have a safe and relaxing Independence Day! 🇺🇸 #FourthOfJuly

We’re presenting interim data from our Phase 1/2 upliFT-D trial for FTD with GRN mutations at #AAIC2025 — the largest global dementia research conference. Excited to connect and accelerate progress with the community. #GeneticMedicines #ClinicalTrials #MedEd

Our team just wrapped #AAIC2025! Thank you to everyone who stopped by our poster to learn more about our gene therapy program. #GeneTherapy #NeurodegenerativeDiseases #MedEd

Today, we shared our Q2 2025 #financialresults along with important #business updates. Check out our recent progress with the upliFT-D clinical trial and what’s ahead here: loom.ly/N0X7rwg $PASG